Algert Global LLC Grows Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Algert Global LLC grew its stake in ADMA Biologics, Inc. (NASDAQ:ADMA) by 72.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 204,388 shares of the biotechnology company’s stock after acquiring an additional 86,098 shares during the quarter. Algert Global LLC owned about 0.09% of ADMA Biologics worth $4,086,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Bank of Montreal Can purchased a new position in ADMA Biologics in the 2nd quarter valued at about $17,886,000. D. E. Shaw & Co. Inc. raised its position in shares of ADMA Biologics by 26.8% in the second quarter. D. E. Shaw & Co. Inc. now owns 6,824,517 shares of the biotechnology company’s stock valued at $76,298,000 after buying an additional 1,442,799 shares during the last quarter. Principal Financial Group Inc. lifted its stake in shares of ADMA Biologics by 785.7% during the third quarter. Principal Financial Group Inc. now owns 1,194,221 shares of the biotechnology company’s stock valued at $23,872,000 after buying an additional 1,059,394 shares during the period. Castleark Management LLC acquired a new stake in ADMA Biologics during the first quarter worth approximately $5,400,000. Finally, First Turn Management LLC purchased a new stake in ADMA Biologics in the 3rd quarter worth approximately $13,293,000. Institutional investors and hedge funds own 75.68% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. Cantor Fitzgerald restated an “overweight” rating and set a $20.00 price objective on shares of ADMA Biologics in a report on Friday, September 20th. HC Wainwright raised their price target on ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday, November 8th. Finally, Raymond James increased their price objective on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a report on Friday, November 8th.

ADMA Biologics Stock Performance

ADMA Biologics stock opened at $21.47 on Tuesday. The company has a market cap of $5.08 billion, a price-to-earnings ratio of 76.68 and a beta of 0.64. ADMA Biologics, Inc. has a 12 month low of $3.60 and a 12 month high of $23.64. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. The stock’s 50-day moving average is $18.86 and its 200-day moving average is $14.95.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.13 by $0.02. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The firm had revenue of $119.84 million for the quarter, compared to analyst estimates of $107.25 million. During the same quarter last year, the firm posted $0.01 earnings per share. Equities analysts anticipate that ADMA Biologics, Inc. will post 0.52 earnings per share for the current year.

Insider Activity at ADMA Biologics

In related news, Director Lawrence P. Guiheen sold 9,000 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $18.47, for a total transaction of $166,230.00. Following the transaction, the director now directly owns 153,941 shares of the company’s stock, valued at approximately $2,843,290.27. The trade was a 5.52 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Brad L. Tade sold 15,000 shares of the company’s stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $21.15, for a total value of $317,250.00. Following the completion of the transaction, the chief financial officer now owns 199,433 shares of the company’s stock, valued at approximately $4,218,007.95. This represents a 7.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 185,011 shares of company stock worth $3,255,204. 3.70% of the stock is currently owned by corporate insiders.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.